. To established a model for predicting clinical efficacy and AEs, polymorphisms in genes including ABC transporters (ABCB1 and ABCG2), UGT1A, and OR2B11 were analyzed by whole-exome sequencing, Sanger sequencing, and DNA microarray. An exponential regression model of the resulting data was used to predict the area under the plasma concentration-time curve (AUC) of axitinib. To validate this prediction model, calculated AUC was compared with actual AUC in 16 additional consecutive patients prospectively evaluated between September 2016 and May 2017. To further evaluate this model for presurgical axitinib, we compared the calculated AUC in this model with best ORR and actual AUCs in 20 patients with advanced RCC treated with neoadjuvant axitinib.
October 2013 and August 2016. To established a model for predicting clinical efficacy and AEs, polymorphisms in genes including ABC transporters (ABCB1 and ABCG2), UGT1A, and OR2B11 were analyzed by whole-exome sequencing, Sanger sequencing, and DNA microarray. An exponential regression model of the resulting data was used to predict the area under the plasma concentration-time curve (AUC) of axitinib. To validate this prediction model, calculated AUC was compared with actual AUC in 16 additional consecutive patients prospectively evaluated between September 2016 and May 2017. To further evaluate this model for presurgical axitinib, we compared the calculated AUC in this model with best ORR and actual AUCs in 20 patients with advanced RCC treated with neoadjuvant axitinib.
RESULTS: Actual AUC significantly correlated with the best ORR (P ¼ 0.0002) and AEs (grade 2-3 hand-foot syndrome, P ¼ 0.0055; and grade 2 hypothyroidism, P ¼ 0.0381). Calculated AUC significantly correlated with actual AUC (P < 0.0001), and correctly predicted best ORR (P ¼ 0.0044) as well as AEs (grade 2-3 hand-foot syndrome, P ¼ 0.0191; and grade 2 hypothyroidism, 0.0082). Surprisingly, hypertension was associated with neither ORR nor AUC. In the validation study, calculated AUC prior to axitinib treatment precisely predicted actual AUC after axitinib treatment in the 16 additional patients (P ¼ 0.0066). Furthermore, in the treatment with neoadjuvant axitinib, calculated AUC was significantly associated with best ORR (P ¼ 0.0278) and actual AUC (P ¼ 0.0042).
CONCLUSIONS: Our pharmacogenetic-based AUC model may offer more precise method to determine optimal initial axitinib doses than hypertension in individuals with advanced RCC. To achieve the best ORR, dose modification of initial axitinib doses should be considered if the calculated AUC value is at the 25th percentile and less in particular with neoadjuvant setting. 
MP72-11 TARGETING SUNITINIB RESISTANT CELLS BY TUMOR SUPPRESSIVE MIRNA-99A-3P THROUGH RIBONUCLEOTIDE REDUCTASE REGULATION IN CLEAR CELL RENAL CELL CARCINOMA
Youichi Osako*, Hirofumi Yoshino, Takashi Sakaguchi, Satoshi Sugita, Shuichi Tatarano, Takashi Yamane, Hideki Enokida, Masayuki Nakagawa, Kagoshima, Japan INTRODUCTION AND OBJECTIVES: Sunitinib is the most common targeting drug for metastatic renal cell carcinoma (RCC), however resistance to sunitinib is a large problem in clinical aspect. In this study, we focused on miR-99a-3p, which showed decreased expression in sunitinib-resistant RCC based on previous screening analyses, and we investigated the mechanism of sunitinib tolerance associated with miR-99a-3p and the molecular network controlled by miR-99a-3p.
METHODS: Expression levels of miR-99a-3p and its candidate target genes in the RCC cell lines (786-o, ACHN, and our sunitinibresistant cell (SU-R-786-o)) and RCC clinical specimens were evaluated by qRT-PCR. For the gain of function study, cell proliferation, apoptosis, and colony formation assay were performed in miR-99a-3p transfected RCC cell lines. Putative target genes were determined by the analyses with publically available database such as GEO and TargetScan, as well as RNA sequencing expression analysis using SU-R-786-o. Loss of functional studies of the target gene was performed using si-RNA. Overall survival between high and low expression of the target gene was analyzed by the Kaplan-Meier method using the database of The Cancer Genome Atlas (TCGA).
RESULTS: The expression levels of miR-99a-3p were down regulated in RCC clinical specimens and the RCC cell lines compared to normal kidneys. In addition, its expression in SU-R-786-o was much lower compared to the parent cell. Restoration of miR-99a-3p in the RCC cells including SU-R-786-o significantly inhibited cell proliferation (p<0.0001) through induction of apoptosis (p<0.0001). RRM2, involved in the synthesis of deoxynucleotides that is necessary for polymerization and repair of DNA, was identified as a direct target by miR-99a-3p based on target analyses. Loss of functional studies using si-RRM2 showed that cell proliferation was significantly inhibited through induction of apoptosis especially in SU-R-786-o (p<0.0001). Kaplan-Meier analysis revealed that the patients (n¼ 534) with high expression of RRM2 showed lower overall survival time than those with low expression according to the TCGA database (p<0.0001).
CONCLUSIONS: miR-99a-3p might have tumor suppressive function through induction of cell apoptosis in sunitinib-resistant RCC cells. To the best of our knowledge, this is the first report demonstrating that miR-99a-3p directly regulate RRM2. The identification of novel target gene regulated by tumor-suppressive miR-99a-3p in sunitinib resistant RCC cells may lead to a better understanding of resistant mechanism and the development of new therapeutic strategies.
Source of Funding: none

MP72-12 CO-TREATMENT WITH L-METHADONE INCREASES THE EFFICACY OF ANTITUMOR AGENTS IN RENAL CELL CARCINOMA CELLS IN VITRO
Birgit Stadlbauer, Heike Pohla, Christian Stief, Alexander Buchner*, Munich, Germany INTRODUCTION AND OBJECTIVES: In leukemia and glioblastoma cells, a significant increase of apoptosis rates was observed in vitro under cytostatic therapy by activation of the m-opioid receptor with methadone. This study investigated the effect of methadone cotreatment in renal cell carcinoma (RCC) cells in the presence of different antitumor agents.
METHODS: The clear-cell RCC cell line RCC-26 was incubated with different antitumor drugs (doxorubicin, mitoxantrone, axitinib and others). The ratio of cells in apoptosis after 5 days was analyzed using flow cytometry with annexin V-APC and 7AAD double staining. In each setting, the cells were co-incubated with various concentrations of L-methadone and D,L-methadone (0-30mg/ml). The opioid antagonist naloxone served as negative control. Additionally, cell proliferation assays (Cell Titer 96 AQueous One Solution, Promega) and cell migration assays (Automated Cellular Analysis System, MetaVi Labs) were conducted. Furthermore, gene expression analysis including pathway analysis was performed using microarrays (Affymetrix GeneChip Prime View with ca. 49,000 transcripts) to reveal changes in cell biology caused by methadone co-treatment.
RESULTS: Incubation of RCC-26 cells with 1mM doxorubicin resulted in 32% apoptosis after 5 days. Co-incubation with L-methadone showed a dose-dependent increase of apoptosis rate up to 78% (2.4-fold increase). The effect of D,L-methadone was similar but less pronounced. Control experiments with naloxone instead of methadone showed no influence on the apoptosis rate. Comparable results were achieved with other tumor cell lines, e.g. A172 glioblastoma cells. RCC-26 proliferation was significantly decreased by co-incubation with L-methadone and doxorubicin vs. one of these drugs alone. Cell migration assays showed a complete inhibition of RCC-26 migration by co-incubation with 10ng/ml L-methadone and 1mM doxorubicin. Microarray analysis identified 333 upregulated and 69 downregulated genes (2-fold change of expression level, p<0.05) caused by L-methadone in RCC-26 cells.
CONCLUSIONS: Co-incubation with L-methadone enhances the therapeutic effect of antitumor drugs in renal cell carcinoma cells and in various other tumor cell lines. The increase of the cytostatic effect depends on the combination of cell line and antitumor agent. The combination of L-methadone with certain antitumor drugs might be a promising new approach to increase the therapeutic efficacy in renal cell carcinoma.
